BioWorld

Feb. 9, 2009

View Archived Issues

Idenix, GSK Team Up in $450M HIV Deal

Idenix Pharmaceuticals Inc. has granted London-based GlaxoSmithKline plc worldwide rights to IDX899, a potential treatment for HIV/AIDS, in a deal that could bring in a potential $450 million for the U.S-based biotech. (BioWorld Today) Read More

Biogen Hits Earnings Estimates, Though Tysabri Sales Fall Short

Read More

FDA Accepts Roxro's NDA for Intranasal Non-Narcotic Painkiller

Read More

Dems Pledge Health Reform Despite Loss of Daschle

Read More

Avigen's Board Rejects BVF Bid; Urges Shareholders to Pass

Read More

GTC's ATryn Wins One OK, Loses on Broader Indication

Read More

Other News To Note

Read More

Financings Roundup

Read More